AI Patent Analysis Toolkit
PatentAgility
by KellDann

Examiner Nyrobi Celestine

Examiner Nyrobi Celestine appears to be about average relative to their peer examiners. Their lifetime grant ratio is 52.0%, they average 2.46 office actions per granted patent, and their rejection profile is dominated by ยง103.

Difficulty vs AU Very Easy
Difficulty vs Group About Average
Difficulty vs TC About Average
Difficulty vs USPTO Very Hard
Average OA / Grant 2.46
Export
Word PDF

Create account to export.

Examiner Details

Observed Examiner Years
6 years (2021-2026)
Phone
(571) 272-0129
Predicted Supervisor
N/A
Supervisor Phone
N/A
Tech Center
3700 - Mechanical Engineering, Manufacturing and Products
Group
3790 - Medical Instruments, Diagnostic Equipment, and Treatment Devices

Metrics

Applications Evaluated
325
Granted Applications
169
Non-Granted Applications
156
Avg OA / Grant
2.46
Last OA Observed
July 2026 (1 months ago)
Art Units Seen
3793 , 3798
Work Groups Seen

Context Comparison

Scope Examiners Lifetime Grant Ratio Avg OA / Grant
This Examiner 1 52.0% 2.46
Art Unit 15 36.3% 2.66
Group 335 39.2% 2.25
Tech Center 2,662 48.9% 2.01
USPTO 16,347 53.5% 1.98

Grant Timeline

0.0% 25.0% 50.0% 75.0% 100.0% 2021 2022 2023 2024 2025 2026
Shaded region marks the last two observed years, where grant outcomes may lag due to recency.
Year Applications Granted Grant Rate
No observed data before 2021; examiner may not yet have been active in the available dataset.
2021 23 12 52.2%
2022 51 42 82.4%
2023 58 43 74.1%
2024 67 59 88.1%
2025 62 13 21.0%
2026 64 0 0.0%

169 family-cache-validated grants; 0 OA-only grant signals.

Rejection Timeline

OA # Office Actions § 101 Percentage § 102 Percentage § 103 Percentage § 112 Percentage
1 314 0.0% 9.2% 82.2% 5.1%
2 222 0.5% 3.6% 82.0% 11.3%
3 110 0.0% 1.8% 84.5% 11.8%
4 46 0.0% 4.3% 78.3% 17.4%
5 15 0.0% 0.0% 73.3% 26.7%
6 5 0.0% 0.0% 80.0% 20.0%
7 3 0.0% 0.0% 66.7% 33.3%
8 2 0.0% 0.0% 100.0% 0.0%
9 1 0.0% 0.0% 100.0% 0.0%
10 1 0.0% 0.0% 100.0% 0.0%

§ 101 Yearly Trend

2024: AI Examples
2025: Aug. Memo
0.0%
2020
0.0%
2021
0.0%
2022
0.0%
2023
0.0%
2024
0.7%
2025
0.0%
2026

Each bar shows the share of this examiner's observed office actions in that year that included a § 101 rejection.